By Katya Ascher and Edouard Becker on Jun 17, 2021
Posted In EU Update, Life Sciences
One of the conditions for obtaining an SPC is that “the product is protected by a basic patent in force”. The Court of Justice of the European Union (CJEU) clariﬁed to what extent a product must be identiﬁed by the claims to meet this condition in Teva, Eli Lilly, and Royalty Pharma. In Eli Lilly,...
By Katya Ascher and Edouard Becker on Jun 10, 2021
Posted In Copyrights, EU Update, Life Sciences, Patents, Trademarks
As a result of the healthcare sector’s growing dependence on software, health IT companies are increasingly taking advantage of globalisation to engage contractors in low wage jurisdictions to develop their user-facing software applications. This can trigger unforeseen legal risks owing to the differing laws across jurisdictions related to the ownership and transfer of intellectual property...